|Classification and external resources|
Helicobacter pylori (), previously named Campylobacter pylori, is a microbial cause. It is also linked to the development of duodenal ulcers and stomach cancer. However, over 80% of individuals infected with the bacterium are asymptomatic and it may play an important role in the natural stomach ecology.
More than 50% of the world's population harbor H. pylori in their upper gastrointestinal tract. Infection is more prevalent in developing countries, and incidence is decreasing in Western countries. H. pylori's helical shape (from which the generic name is derived) is thought to have evolved to penetrate the mucoid lining of the stomach.
- 1 Signs and symptoms
- 2 Microbiology
- 3 Pathophysiology
- 4 Diagnosis
- 5 Prevention
- 6 Treatment
- 7 Prognosis
- 8 Survival of H. pylori
- 9 Epidemiology
- 10 Evolution
- 11 History
- 12 References
- 13 External links
Signs and symptoms
Up to 85% of people infected with H. pylori never experience symptoms or complications. Acute infection may appear as an acute gastritis with abdominal pain (stomach ache) or nausea. Where this develops into chronic gastritis, the symptoms, if present, are often those of non-ulcer dyspepsia: stomach pains, nausea, bloating, belching, and sometimes vomiting or black stool.
Individuals infected with H. pylori have a 10 to 20% lifetime risk of developing peptic ulcers and a 1 to 2% risk of acquiring stomach cancer. Inflammation of the pyloric antrum is more likely to lead to duodenal ulcers, while inflammation of the corpus (body of the stomach) is more likely to lead to gastric ulcers and gastric carcinoma. However, H. pylori possibly plays a role only in the first stage that leads to common chronic inflammation, but not in further stages leading to carcinogenesis. A meta-analysis conducted in 2009 concluded the eradication of H. pylori reduces gastric cancer risk in previously infected individuals, suggesting the continued presence of H. pylori constitutes a relative risk factor of 65% for gastric cancers; in terms of absolute risk, the increase was from 1.1% to 1.7%.
H. pylori has also been associated with colorectal polyps and colorectal cancer.
(Marshall et al. 1985) Goodwin et al., 1989
H. pylori is a helix-shaped (classified as a curved rod, not spirochaete) Gram-negative bacterium about 3 μm long with a diameter of about 0.5 μm. It is microaerophilic; that is, it requires oxygen, but at lower concentration than is found in the atmosphere. It contains a hydrogenase which can be used to obtain energy by oxidizing molecular hydrogen (H2) produced by intestinal bacteria. It produces oxidase, catalase, and urease. It is capable of forming biofilms and can convert from spiral to a possibly viable but nonculturable coccoid form, both likely to favor its survival and be factors in the epidemiology of the bacterium.
H. pylori possesses five major outer membrane protein families. The largest family includes known and putative adhesins. The other four families are porins, iron transporters, flagellum-associated proteins, and proteins of unknown function. Like other typical Gram-negative bacteria, the outer membrane of H. pylori consists of phospholipids and lipopolysaccharide (LPS). The O antigen of LPS may be fucosylated and mimic Lewis blood group antigens found on the gastric epithelium. The outer membrane also contains cholesterol glucosides, which are found in few other bacteria. H. pylori has four to six lophotrichous flagella; all gastric and enterohepatic Helicobacter species are highly motile owing to flagella. The characteristic sheathed flagellar filaments of Helicobacter are composed of two copolymerized flagellins, FlaA and FlaB.
H. pylori can be demonstrated in tissue by Gram stain, Giemsa stain, haematoxylin-eosin stain, Warthin-Starry silver stain, acridine-orange stain, and phase-contrast microscopy.
H. pylori consists of a large diversity of strains, and the genomes of three have been completely sequenced. The genome of the strain "26695" consists of about 1.7 million base pairs, with some 1,550 genes. The two sequenced strains show large genetic differences, with up to 6% of the nucleotides differing.
Study of the H. pylori genome is centered on attempts to understand kb-long Cag pathogenicity island (a common gene sequence believed responsible for pathogenesis) that contains over 40 genes. This pathogenicity island is usually absent from H. pylori strains isolated from humans who are carriers of H. pylori but remain asymptomatic.
The cagA gene codes for one of the major H. pylori virulence proteins. Bacterial strains with the cagA gene are associated with an ability to cause ulcers. The cagA gene codes for a relatively long (1186-amino acid) protein. The cag pathogenicity island (PAI) has about 30 genes, part of which code for a complex type IV secretion system. The low GC-content of the cag PAI relative to the rest of the Helicobacter genome suggests the island was acquired by horizontal transfer from another bacterial species.
Adaptation to the stomach’s acidic environment
To avoid the acidic environment of the interior of the stomach (lumen), H. pylori uses its flagella to burrow into the mucus lining the stomach to reach the epithelial cells underneath, where the pH is more neutral. H. pylori is able to sense the pH gradient in the mucus and move towards the less acidic region (chemotaxis). This also keeps the bacteria from being swept away into the lumen with the bacteria’s mucus environment, which is constantly moving from its site of creation at the epithelium to its dissolution at the lumen interface.
H. pylori is found in the mucus, on the inner surface of the epithelium, and occasionally inside the epithelial cells themselves. It adheres to the epithelial cells by producing adhesins, which bind to lipids and carbohydrates in the epithelial cell membrane. One such adhesion, BabA, binds to the Lewis b antigen displayed on the surface of stomach epithelial cells. Another such adhesion, SabA, binds to increased levels of sialyl-Lewis x antigen expressed on gastric mucosa.
In addition to using chemotaxis to avoid areas of low pH, H. pylori also neutralizes the acid in its environment by producing large amounts of urease, which breaks down the urea present in the stomach to carbon dioxide and ammonia. The ammonia, which is basic, then neutralizes stomach acid.
Inflammation, gastritis, and ulcer
H. pylori harms the stomach and duodenal linings by several mechanisms. The ammonia produced to regulate pH is toxic to epithelial cells, as are biochemicals produced by H. pylori such as proteases, vacuolating cytotoxin A (VacA) [this damages epithelial cells, disrupts tight junctions and causes apoptosis], and certain phospholipases. Cytotoxin associated gene CagA can also cause inflammation and is potentially a carcinogen.
Colonization of the stomach by H. pylori can result in chronic gastritis, an inflammation of the stomach lining, at the site of infection. Helicobacter cysteine-rich proteins (Hcp), particularly HcpA (hp0211), are known to trigger an immune response, causing inflammation. Chronic gastritis is likely to underlie H. pylori-related diseases.
Ulcers in the stomach and duodenum result when the consequences of inflammation allow stomach acid and the digestive enzyme pepsin to overwhelm the mechanisms that protect the stomach and duodenal mucous membranes. The location of colonization of H. pylori, which affects the location of the ulcer, depends on the acidity of the stomach. In people producing large amounts of acid, H. pylori colonizes near the pyloric antrum (exit to the duodenum) to avoid the acid-secreting parietal cells at the fundus (near the entrance to the stomach). In people producing normal or reduced amounts of acid, H. pylori can also colonize the rest of the stomach.
The inflammatory response caused by bacteria colonizing near the pyloric antrum induces G cells in the antrum to secrete the hormone gastrin, which travels through the bloodstream to parietal cells in the fundus. Gastrin stimulates the parietal cells to secrete more acid into the stomach lumen, and over time increases the number of parietal cells, as well. The increased acid load damages the duodenum, which may eventually result in ulcers forming in the duodenum.
When H. pylori colonizes other areas of the stomach, the inflammatory response can result in atrophy of the stomach lining and eventually ulcers in the stomach. This also may increase the risk of stomach cancer.
The Cag pathogenicity island
The pathogenicity of H. pylori may be increased by genes of the cag pathogenicity island. About 50–70% of H. pylori strains in Western countries carry the cag pathogenicity island (cag PAI). Western patients infected with strains carrying the cag PAI have a stronger inflammatory response in the stomach and are at a greater risk of developing peptic ulcers or stomach cancer than those infected with strains lacking the island. Following attachment of H. pylori to stomach epithelial cells, the type IV secretion system expressed by the cag PAI "injects" the inflammation-inducing agent, peptidoglycan, from their own cell wall into the epithelial cells. The injected peptidoglycan is recognized by the cytoplasmic pattern recognition receptor (immune sensor) Nod1, which then stimulates expression of cytokines that promote inflammation.
The type-IV secretion apparatus also injects the cag PAI-encoded protein CagA into the stomach's epithelial cells, where it disrupts the cytoskeleton, adherence to adjacent cells, intracellular signaling, cell polarity, and other cellular activities. Once inside the cell, the CagA protein is phosphorylated on tyrosine residues by a host cell membrane-associated tyrosine kinase (TK). CagA then allosterically activates protein tyrosine phosphatase/protooncogene Shp2. Pathogenic strains of H. pylori have been shown to activate the epidermal growth factor receptor (EGFR), a membrane protein with a TK domain. Activation of the EGFR by H. pylori is associated with altered signal transduction and gene expression in host epithelial cells that may contribute to pathogenesis. A C-terminal region of the CagA protein (amino acids 873–1002) has also been suggested to be able to regulate host cell gene transcription, independent of protein tyrosine phosphorylation. A great deal of diversity exists between strains of H. pylori, and the strain with which one is infected is predictive of the outcome.
Two related mechanisms by which H. pylori could promote cancer are under investigation. One mechanism involves the enhanced production of free radicals near H. pylori and an increased rate of host cell mutation. The other proposed mechanism has been called a "perigenetic pathway", and involves enhancement of the transformed host cell phenotype by means of alterations in cell proteins, such as adhesion proteins. H. pylori has been proposed to induce inflammation and locally high levels of TNF-α and/or interleukin 6 (IL-6). According to the proposed perigenetic mechanism, inflammation-associated signaling molecules, such as TNF-α, can alter gastric epithelial cell adhesion and lead to the dispersion and migration of mutated epithelial cells without the need for additional mutations in tumor suppressor genes, such as genes that code for cell adhesion proteins.
Colonization with H. pylori is not a disease in and of itself, but a condition associated with a number of disorders of the upper gastrointestinal tract. Testing for H. pylori is recommended if there is peptic ulcer disease, low grade gastric MALT lymphoma, after endoscopic resection of early gastric cancer, if there are first degree relatives with gastric cancer, and in certain cases of dyspepsia, not routinely. Several ways of testing exist. One can test noninvasively for H. pylori infection with a blood antibody test, stool antigen test, or with the carbon urea breath test (in which the patient drinks 14C— or 13C-labelled urea, which the bacterium metabolizes, producing labelled carbon dioxide that can be detected in the breath). Also, a urine ELISA test with a 96% sensitivity and 79% specificity is available. None of the test methods is completely failsafe. Even biopsy is dependent on the location of the biopsy. Blood antibody tests, for example, range from 76% to 84% sensitivity. Some drugs can affect H. pylori urease activity and give false negatives with the urea-based tests. The most reliable method for detecting H. pylori infection is with a histological examination from two sites after endoscopic biopsy, combined with either a rapid urease test or microbial culture.
H. pylori is a major cause of certain diseases of the upper gastrointestinal tract. Rising antibiotic resistance increases the need to search for new therapeutic strategies; this might include prevention in form of vaccination.  Much work has been done on developing viable vaccines aimed at providing an alternative strategy to control H. pylori infection and related diseases, including stomach cancer.  Researchers are studying different adjuvants, antigens, and routes of immunization to ascertain the most appropriate system of immune protection; however, most of the research only recently moved from animal to human trials.  An economic evaluation of the use of a potential H. pylori vaccine in babies found its introduction could, at least in the Netherlands, prove cost-effective for the prevention of peptic ulcer and stomach cancer.  A similar approach has also been studied for the United States. 
The presence of bacteria in the stomach may be beneficial, reducing the prevalence of asthma,  rhinitis,  dermatitis,  inflammatory bowel disease,  gastroesophageal reflux disease,  and esophageal cancer  by influencing systemic immune responses.  
Recent evidence suggests that H. pylori may be beneficial "by helping regulate levels of stomach acids, thus creating an environment that suits itself and its host. If the stomach churns out too much acid for the bacteria to thrive, for example, strains of the bacteria that contain a gene called cagA start producing proteins that signal the stomach to tone down the flow of acid, in susceptible people, however, cagA has an unwelcome side effect: provoking the ulcers that earned H. pylori its nasty rap."
H. pylori may play a role in regulating appetite- "When you have H. pylori, you have a postprandial decrease in ghrelin. When you eradicate H. pylori, you lose that." Gherelin is a hormone "which tells the brain that the body needs to eat." 
Once H. pylori is detected in a person with a peptic ulcer, the normal procedure is to eradicate it and allow the ulcer to heal. The standard first-line therapy is a one-week "triple therapy" consisting of proton pump inhibitors such as omeprazole and the antibiotics clarithromycin and amoxicillin. Variations of the triple therapy have been developed over the years, such as using a different proton pump inhibitor, as with pantoprazole or rabeprazole, or replacing amoxicillin with metronidazole for people who are allergic to penicillin. Such a therapy has revolutionized the treatment of peptic ulcers and has made a cure to the disease possible. Previously, the only option was symptom control using antacids, H2-antagonists or proton pump inhibitors alone.
An increasing number of infected individuals are found to harbor antibiotic-resistant bacteria. This results in initial treatment failure and requires additional rounds of antibiotic therapy or alternative strategies, such as a quadruple therapy, which adds a bismuth colloid, such as bismuth subsalicylate. For the treatment of clarithromycin-resistant strains of H. pylori, the use of levofloxacin as part of the therapy has been suggested.
Ingesting lactic acid bacteria exerts a suppressive effect on H. pylori infection in both animals and humans, and supplementing with Lactobacillus- and Bifidobacterium-containing yogurt improved the rates of eradication of H. pylori in humans.
H. pylori colonizes the stomach and induces chronic gastritis, a long-lasting inflammation of the stomach. The bacterium persists in the stomach for decades in most people. Most individuals infected by H. pylori will never experience clinical symptoms despite having chronic gastritis. About 10–20% of those colonized by H. pylori will ultimately develop gastric and duodenal ulcers. H. pylori infection is also associated with a 1–2% lifetime risk of stomach cancer and a less than 1% risk of gastric MALT lymphoma.
In the absence of treatment, H. pylori infection—once established in its gastric niche—is widely believed to persist for life. In the elderly, however, infection likely can disappear as the stomach's mucosa becomes increasingly atrophic and inhospitable to colonization. The proportion of acute infections that persist is not known, but several studies that followed the natural history in populations have reported apparent spontaneous elimination.
Mounting evidence suggests H. pylori has an important role in protection from some diseases. The incidence of acid reflux disease, Barrett's esophagus, and esophageal cancer have been rising dramatically at the same time as H. pylori's presence decreases. In 1996, Martin J. Blaser advanced the hypothesis that H. pylori has a beneficial effect: by regulating the acidity of the stomach contents. The hypothesis is not universally accepted as several randomized controlled trials failed to demonstrate worsening of acid reflux disease symptoms following eradication of H. pylori. Nevertheless, Blaser has reasserted his view that H. pylori is a member of the normal flora of the stomach. He postulates that the changes in gastric physiology caused by the loss of H. pylori account for the recent increase in incidence of several diseases, including type 2 diabetes, obesity, and asthma. His group has recently shown that H. pylori colonization is associated with a lower incidence of childhood asthma.
Survival of H. pylori
The pathogenesis of H. pylori depends on its ability to survive in the harsh gastric environment characterized by acidity, peristalsis, and attack by phagocytes accompanied by release of reactive oxygen species. In particular, H. pylori elicits an oxidative stress response during host colonization. This oxidative stress response induces potentially lethal and mutagenic oxidative DNA adducts in the H. pylori genome.
Vulnerability to oxidative stress and oxidative DNA damage occurs commonly in many studied bacterial pathogens, including Neisseria gonorrhoeae, Hemophilus influenzae, Streptococcus pneumoniae, Streptococcus mutans and Helicobacter pylori. For each of these pathogens, surviving the DNA damage induced by oxidative stress appears to be supported by transformation-mediated recombinational repair. Thus, transformation and recombinational repair appear to contribute to successful infection.
 In H. pylori, homologous recombination is required for repairing DNA double-strand breaks (DSBs). The AddAB helicase-nuclease complex resects DSBs and loads RecA onto single-strand DNA (ssDNA), which then mediates strand exchange, leading to homologous recombination and repair. The requirement of RecA plus AddAB for efficient gastric colonization suggests, in the stomach, H. pylori is either exposed to double-strand DNA damage that must be repaired or requires some other recombination-mediated event. In particular, natural transformation is increased by DNA damage in H. pylori, and a connection exists between the DNA damage response and DNA uptake in H. pylori, suggesting natural competence contributes to persistence of H. pylori in its human host and explains the retention of competence in most clinical isolates.
RuvC protein is essential to the process of recombinational repair since it resolves intermediates in this process termed Holliday junctions. H. pylori mutants that are defective in RuvC have increased sensitivity to DNA-damaging agents and to oxidative stress, exhibit reduced survival within macrophages, and are unable to establish successful infection in a mouse model. Similarly, RecN protein plays an important role in DSB repair in H. pylori. An H. pylori recN mutant displays an attenuated ability to colonize mouse stomachs, highlighting the importance of recombinational DNA repair in survival of H. pylori within its host.
At least half the world's population is infected by the bacterium, making it the most widespread infection in the world. Actual infection rates vary from nation to nation; the developing world has much higher infection rates than the West (Western Europe, North America, Australasia), where rates are estimated to be around 25%. The age at which this bacterium is acquired seems to influence the possible pathologic outcome of the infection : people infected with it at an early age are likely to develop more intense inflammation that may be followed by atrophic gastritis with a higher subsequent risk of gastric ulcer, gastric cancer, or both. Acquisition at an older age brings different gastric changes more likely to lead to duodenal ulcer. Infections are usually acquired in early childhood in all countries. However, the infection rate of children in developing nations is higher than in industrialized nations, probably due to poor sanitary conditions, perhaps combined with lower antibiotics usage for unrelated pathologies. In developed nations, it is currently uncommon to find infected children, but the percentage of infected people increases with age, with about 50% infected for those over the age of 60 compared with around 10% between 18 and 30 years. The higher prevalence among the elderly reflects higher infection rates in the past when the individuals were children rather than more recent infection at a later age of the individual. In the United States, prevalence appears to be higher in African-American and Hispanic populations, most likely due to socioeconomic factors. The lower rate of infection in the West is largely attributed to higher hygiene standards and widespread use of antibiotics. Despite high rates of infection in certain areas of the world, the overall frequency of H. pylori infection is declining. However, antibiotic resistance is appearing in H. pylori; many metronidazole- and clarithromycin-resistant strains are found in most parts of the world.
H. pylori is contagious, although the exact route of transmission is not known. Person-to-person transmission by either the oral-oral or fecal-oral route is most likely. Consistent with these transmission routes, the bacteria have been isolated from feces, saliva, and dental plaque of some infected people. Findings suggest H. pylori is more easily transmitted by gastric mucus than saliva Transmission occurs mainly within families in developed nations, yet can also be acquired from the community in developing countries. H. pylori may also be transmitted orally by means of fecal matter through the ingestion of waste-tainted water, so a hygienic environment could help decrease the risk of H. pylori infection.
H. pylori migrated out of Africa along with its human host circa 60,000 years ago. Its subsequent evolution created seven prototypes—Europe (isolated from Europe, the Middle East, India, and Iran), NE Africa (from northeast Africa), Africa1 (from countries in Western Africa and South Africa), Africa2 (from South Africa), Asia2 (from Northern India and among isolates from Bangladesh, Thailand, and Malaysia), Sahul (from Australian Aboriginals and Papua New Guineans) and East Asia with the subpopulations E Asia (from East Asians), Maori (from Taiwanese Aboriginals, Melanesians and Polynesians) and Amerind (Native Americans). The precursors of these prototypes have been named ancestral Europe1, ancestral Europe2, ancestral East Asia, ancestral Africa1, ancestral Africa2, and ancestral Sahul. These ancestral prototypes appear to have originated in Africa and Central and East Asia. European and African strains were introduced into the Americas along with its colonisation—both thousands of years ago and more recently in the slave trade.
Recent research states that genetic diversity in H. pylori increases with geographic distance from East Africa, the birthplace of modern humans. Using the genetic diversity data, researchers have created simulations that indicate the bacteria seem to have spread from East Africa around 58,000 years ago. Their results indicate modern humans were already infected by H. pylori before their migrations out of Africa, and it has remained associated with human hosts since that time.
H. pylori was first discovered in the stomachs of patients with gastritis and stomach ulcers in 1982 by Dr. Barry Marshall and Dr. Robin Warren of Perth, Western Australia. At the time, the conventional thinking was that no bacterium can live in the human stomach, as the stomach produced extensive amounts of acid of a strength similar to the acid found in a car battery. Marshall and Warren rewrote the textbooks with reference to what causes gastritis and gastric ulcers. In recognition of their discovery, they were awarded the 2005 Nobel Prize in Physiology or Medicine.
Previous to the research of Marshall and Warren, German scientists found spiral-shaped  Several small studies conducted in the early 20th century demonstrated the presence of curved rods in the stomach of many patients with peptic ulcers and stomach cancer. Interest in the bacteria waned, however, when an American study published in 1954 failed to observe the bacteria in 1180 stomach biopsies.
Interest in understanding the role of bacteria in stomach diseases was rekindled in the 1970s, with the visualization of bacteria in the stomach of gastric ulcer patients. The bacterium had also been observed in 1979, by Australian pathologist Robin Warren, who did further research on it with Australian physician Barry Marshall beginning in 1981. After numerous unsuccessful attempts at culturing the bacteria from the stomach, they finally succeeded in visualizing colonies in 1982, when they unintentionally left their Petri dishes incubating for five days over the Easter weekend. In their original paper, Warren and Marshall contended that most stomach ulcers and gastritis were caused by infection by this bacterium and not by stress or spicy food, as had been assumed before.
Although some skepticism was expressed initially, numerous research groups within several years verified the association of H. pylori with gastritis and, to a lesser extent, ulcers. To demonstrate H. pylori caused gastritis and was not merely a bystander, Marshall drank a beaker of H. pylori culture. He became ill with nausea and vomiting several days later. An endoscopy 10 days after inoculation revealed signs of gastritis and the presence of H. pylori. These results suggested H. pylori was the causative agent of gastritis. Marshall and Warren went on to demonstrate antibiotics are effective in the treatment of many cases of gastritis. In 1987, the Sydney gastroenterologist Thomas Borody invented the first triple therapy for the treatment of duodenal ulcers. In 1994, the National Institutes of Health (USA) published an opinion stating most recurrent duodenal and gastric ulcers were caused by H. pylori, and recommended antibiotics be included in the treatment regimen.
The bacterium was initially named Campylobacter pyloridis, then renamed C. pylori (pylori being the genitive of pylorus) to correct a Latin grammar error. When 16S ribosomal RNA gene sequencing and other research showed in 1989 that the bacterium did not belong in the genus Campylobacter, it was placed in its own genus, Helicobacter. The genus derived from the ancient Greek hělix/έλιξ "spiral" or "coil". The specific epithet pylōri means "of the pylorus" or pyloric valve (the circular opening leading from the stomach into the duodenum), from the Ancient Greek word πυλωρός, which means gatekeeper.
- Giusti, Cristiano (2004). "Association of Helicobacter pylori with central serous chorioretinopathy: Hypotheses regarding pathogenesis". Medical Hypotheses 63 (3): 524–7.
- Ahnoux-Zabsonre, A.; Quaranta, M.; Mauget-Faÿsse, M. (2004). "Prévalence de l'Helicobacter pylori dans la choriorétinopathie séreuse centrale et l'épithéliopathie rétinienne diffuse" [Prevalence of Helicobacter pylori in central serous chorioretinopathy and diffuse retinal epitheliopathy: a complementary study]. Journal Français d'Ophtalmologie (in French) 27 (10): 1129–33.
- Cotticelli, L; Borrelli, M; d'Alessio, AC; Menzione, M; Villani, A; Piccolo, G; Montella, F; Iovene, MR; Romano, M (2006). "Central serous chorioretinopathy and Helicobacter pylori". European journal of ophthalmology 16 (2): 274–8.
- Blaser, M. J. (2006). "Who are we? Indigenous microbes and the ecology of human diseases". EMBO Reports 7 (10): 956–60.
- Yamaoka, Yoshio (2008). Helicobacter pylori: Molecular Genetics and Cellular Biology. Caister Academic Pr.
- Brown LM (2000). : epidemiology and routes of transmission"Helicobacter pylori". Epidemiol Rev 22 (2): 283–97.
- Bytzer P, Dahlerup JF, Eriksen JR, Jarbøl DE, Rosenstock S, Wildt S (April 2011). "Diagnosis and treatment of Helicobacter pylori infection". Dan Med Bull 58 (4): C4271.
- Butcher, Graham P. (2003). Gastroenterology: An Illustrated Colour Text. Elsevier Health Sciences. p. 25.
- Butcher 2003, pp. 24–5
- Ryan, Kenneth (2010). Sherris Medical Microbiology. McGraw-Hill. pp. 573, 576.
- Kusters JG, van Vliet AH, Kuipers EJ (July 2006). Infection"Helicobacter pylori"Pathogenesis of . Clin Microbiol Rev 19 (3): 449–90.
- Suerbaum S, Michetti P (October 2002). "Helicobacter pylori infection". N. Engl. J. Med. 347 (15): 1175–86.
- Fuccio, L; Zagari, RM; Eusebi, LH; Laterza, L; Cennamo, V; Ceroni, L; Grilli, D; Bazzoli, F (2009). "Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?". Ann Intern Med 151 (2): 121–8.
- Wu, Q.; Yang, Z.-P.; Xu, P.; Gao, L.-C.; Fan, D.-M. (2013). "Association betweenHelicobacter pyloriinfection and the risk of colorectal neoplasia: a systematic review and meta-analysis". Colorectal Disease 15 (7): e352–e364.
- Olson JW, Maier RJ (November 2002). "Molecular hydrogen as an energy source for Helicobacter pylori". Science 298 (5599): 1788–90.
- Stark RM, Gerwig GJ, Pitman RS et al. (February 1999). "Biofilm formation by Helicobacter pylori". Lett Appl Microbiol 28 (2): 121–6.
- Chan WY, Hui PK, Leung KM, Chow J, Kwok F, Ng CS (October 1994). "Coccoid forms of Helicobacter pylori in the human stomach". Am J Clin Pathol 102 (4): 503–7.
- Josenhans C, Eaton KA, Thevenot T, Suerbaum S (August 2000). by Reversible Length Variation of a Short Homopolymeric Sequence Repeat in fliP, a Gene Encoding a Basal Body Protein"Helicobacter pylori"Switching of Flagellar Motility in . Infect Immun 68 (8): 4598–603.
- Rust M, Schweinitzer T, Josenhans C (2008). "Helicobacter Flagella, Motility and Chemotaxis". In Yamaoka Y. Helicobacter pylori: Molecular Genetics and Cellular Biology. Caister Academic Press.
- Tomb JF, White O, Kerlavage AR et al. (August 1997). "The complete genome sequence of the gastric pathogen Helicobacter pylori". Nature 388 (6642): 539–47.
- 26695 and J99 strains"H. pylori"Genome information for the . Institut Pasteur. 2002. Retrieved 1 September 2008.
- 26695, complete genome"Helicobacter pylori". National Center for Biotechnology Information. Retrieved 1 September 2008.
- J99, complete genome"Helicobacter pylori". National Center for Biotechnology Information. Retrieved 1 September 2008.
- Oh JD, Kling-Bäckhed H, Giannakis M et al. (June 2006). strain: Evolution during disease progression"Helicobacter pylori"The complete genome sequence of a chronic atrophic gastritis . Proc Natl Acad Sci U.S.A. 103 (26): 9999–10004.
- Baldwin DN, Shepherd B, Kraemer P et al. (February 2007). Genes That Contribute to Stomach Colonization"Helicobacter pylori"Identification of . Infect Immun 75 (2): 1005–16.
- Broutet N, Marais A, Lamouliatte H et al. (April 2001). Triple Therapies in Patients with Nonulcer Dyspepsia"Helicobacter pylori"cagA Status and Eradication Treatment Outcome of Anti-. J Clin Microbiol 39 (4): 1319–22.
- Amieva MR, El-Omar EM (January 2008). "Host-bacterial interactions in Helicobacter pylori infection". Gastroenterology 134 (1): 306–23.
- Schreiber S, Konradt M, Groll C et al. (April 2004). in the gastric mucus"Helicobacter pylori"The spatial orientation of . Proc. Natl. Acad. Sci. U.S.A. 101 (14): 5024–9.
- Petersen AM, Krogfelt KA (May 2003). "Helicobacter pylori: an invading microorganism? A review". FEMS Immunol. Med. Microbiol. 36 (3): 117–26.
- Ilver D, Arnqvist A, Ogren J et al. (January 1998). "Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging". Science 279 (5349): 373–7.
- Mahdavi J, Sondén B, Hurtig M et al. (July 2002). SabA Adhesin in Persistent Infection and Chronic Inflammation"Helicobacter pylori". Science 297 (5581): 573–8.
- Smoot DT (December 1997). "How does Helicobacter pylori cause mucosal damage? Direct mechanisms". Gastroenterology 113 (6 Suppl): S31–4; discussion S50.
- Hatakeyama, M; Higashi, H (2005). "Helicobacter pylori CagA: A new paradigm for bacterial carcinogenesis". Cancer Science 96 (12): 835–43.
- Dumrese C, Slomianka L, Ziegler U et al. (May 2009). "The secreted Helicobacter cysteine-rich protein A causes adherence of human monocytes and differentiation into a macrophage-like phenotype".
- Shiotani A, Graham DY (November 2002). "Pathogenesis and therapy of gastric and duodenal ulcer disease". Med. Clin. North Am. 86 (6): 1447–66, viii.
- Dixon MF (February 2000). "Patterns of inflammation linked to ulcer disease". Baillieres Best Pract Res Clin Gastroenterol 14 (1): 27–40.
- Blaser MJ, Atherton JC (February 2004). persistence: biology and disease"Helicobacter pylori". J. Clin. Invest. 113 (3): 321–33.
- Schubert ML, Peura DA (June 2008). "Control of gastric acid secretion in health and disease". Gastroenterology 134 (7): 1842–60.
- Suerbaum S, Michetti P (October 2002). "Helicobacter pylori infection". N. Engl. J. Med. 347 (15): 1175–86.
- Peek RM, Crabtree JE (January 2006). "Helicobacter infection and gastric neoplasia". J. Pathol. 208 (2): 233–48.
- Viala J, Chaput C, Boneca IG et al. (November 2004). "Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island". Nat. Immunol. 5 (11): 1166–74.
- Backert S, Selbach M (August 2008). "Role of type IV secretion in Helicobacter pylori pathogenesis". Cell. Microbiol. 10 (8): 1573–81.
- Hatakeyama, M (Sep 2004). "Oncogenic mechanisms of the Helicobacter pylori CagA protein". Nat Rev Cancer (United States) 4 (9): 688–94.
- Tsuji S, Kawai N, Tsujii M, Kawano S, Hori M (July 2003). "Review article: inflammation-related promotion of gastrointestinal carcinogenesis--a perigenetic pathway". Aliment. Pharmacol. Ther. 18 (Suppl 1): 82–9.
- Suganuma M, Yamaguchi K, Ono Y et al. (July 2008). "TNF-α-inducing protein, a carcinogenic factor secreted from H. pylori, enters gastric cancer cells". Int. J. Cancer 123 (1): 117–22.
- Stenström B, Mendis A, Marshall B (August 2008). "Helicobacter pylori—The latest in diagnosis and treatment". Aust Fam Physician 37 (8): 608–12.
- Logan RP, Walker MM (October 2001). infection"Helicobacter pylori"Epidemiology and diagnosis of . BMJ 323 (7318): 920–2.
- Selgrad M, Malfertheiner P (October 2008). "New strategies for Helicobacter pylori eradication". Curr Opin Pharmacol 8 (5): 593–7.
- Blanchard, T G; Nedrud, J G (2010). "9. Helicobacter pylori Vaccines". In Sutton, Philip; Mitchell, Hazel. Helicobacter Pylori in the 21st Century. Mitchell, Hazel. CABI. pp. 167–189.
- Kabir S (April 2007). "The current status of Helicobacter pylori vaccines: a review". Helicobacter 12 (2): 89–102.
- de Vries R, Klok RM, Brouwers JR, Postma MJ (February 2009). "Cost-effectiveness of a potential future Helicobacter pylori vaccine in the Netherlands: the impact of varying the discount rate for health". Vaccine 27 (6): 846–52.
- Rupnow MF, Chang AH, Shachter RD, Owens DK, Parsonnet J (October 2009). "Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States". J. Infect. Dis. 200 (8): 1311–7.
- Salama, N. R. et al. Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori. Nature Reviews Microbiology 11, 385–399 (2013)
- Blaser, M. Antibiotic overuse: Stop the killing of beneficial bacteria. Nature 476, 393–394 (2011)
- Willyard, C. Gut reaction. Nature 479, S5–S7 (2011)
- Ackerman, Jennifer; Blaser, Martin (2012-06-01). "How Bacteria in Our Bodies Protect Our Health". Scientific American (Scientific American, a division of Nature America, Inc.) (June 1, 2012): 42. Retrieved 2014-11-18.
- Malfertheiner, P; Megraud, F; O'Morain, CA; Atherton, J; Axon, AT; Bazzoli, F; Gensini, GF; Gisbert, JP; Graham, DY; Rokkas, T; El-Omar, EM; Kuipers, EJ; European Helicobacter Study, Group (May 2012). infection—the Maastricht IV/ Florence Consensus Report"Helicobacter pylori"Management of . Gut 61 (5): 646–64.
- Malfertheiner P, Megraud F, O'Morain C et al. (June 2007). infection: the Maastricht III Consensus Report"Helicobacter pylori"Current concepts in the management of . Gut 56 (6): 772–81.
- Rauws EA, Tytgat GN (May 1990). "Cure of duodenal ulcer associated with eradication of Helicobacter pylori". Lancet 335 (8700): 1233–5.
- Graham DY, Lew GM, Evans DG, Evans DJ, Klein PD (August 1991). "Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial". Ann. Intern. Med. 115 (4): 266–9.
- Fischbach L, Evans EL (August 2007). "Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori". Aliment. Pharmacol. Ther. 26 (3): 343–57.
- Graham DY, Shiotani A (June 2008). infections"Helicobacter pylori"Newer concepts regarding resistance in the treatment . Nat Clin Pract Gastroenterol Hepatol 5 (6): 321–31.
- Perna F, Zullo A, Ricci C, Hassan C, Morini S, Vaira D (November 2007). "Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance". Dig Liver Dis 39 (11): 1001–5.
- Hsu PI, Wu DC, Chen A et al. (June 2008). "Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures". Eur. J. Clin. Invest. 38 (6): 404–9.
- Wang KY, Li SN, Liu CS et al. (September 2004). "Helicobacter pylori"Effects of ingesting Lactobacillus- and Bifidobacterium-containing yogurt in subjects with colonized .
- J. K. Moon, J. R. Kim et al: Analysis and anti-Helicobacter activity of sulforaphane and related compounds present in broccoli (Brassica oleracea L.) sprouts. In: Journal of Agricultural and Food Chemistry. Volume 58, Number 11, June 2010, pp 6672–6677, ISSN 1520-5118. doi:10.1021/jf1003573. PMID 20459098.
- J. W. Fahey, X. Haristoy et al: Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. In: PNAS. Volume 99, Number 11, May 2002, pp 7610–7615, ISSN 0027-8424. doi:10.1073/pnas.112203099. PMID 12032331. PMC 124299.
- X. Haristoy, K. Angioi-Duprez u. a.: Efficacy of sulforaphane in eradicating Helicobacter pylori in human gastric xenografts implanted in nude mice. In: Antimicrobial agents and chemotherapy. Volume 47, Number 12, December 2003, pp 3982–3984, ISSN 0066-4804. PMID 14638516. PMC 296232.
- Goodman KJ, O'rourke K, Day RS et al. (December 2005). "Dynamics of Helicobacter pylori infection in a US-Mexico cohort during the first two years of life". Int J Epidemiol 34 (6): 1348–55.
- Goodman KJ, Cockburn M (March 2001). "The role of epidemiology in understanding the health effects of Helicobacter pylori". Epidemiology 12 (2): 266–71.
- Blaser MJ (February 2005). "An endangered species in the stomach". Sci. Am. 292 (2): 38–45.
- Graham DY, Yamaoka Y, Malaty HM (November 2007). and the Dire Consequences Hypothesis"Helicobacter pylori"Contemplating the Future without . Helicobacter 12 (Suppl 2): 64–8.
- Delaney B, McColl K (August 2005). "Review article: Helicobacter pylori and gastro-oesophageal reflux disease". Aliment. Pharmacol. Ther. 22 (Suppl 1): 32–40.
- Blaser MJ (October 2006). "Who are we? Indigenous microbes and the ecology of human diseases". EMBO Reports 7 (10): 956–60.
- Blaser MJ, Chen Y, Reibman J (May 2008). "Does Helicobacter pylori protect against asthma and allergy?". Gut 57 (5): 561–7.
- Chen Y, Blaser MJ (August 2008). "Helicobacter pylori colonization is inversely associated with childhood asthma". J. Infect. Dis. 198 (4): 553–60.
- Olczak AA, Olson JW, Maier RJ (June 2002). "Helicobacter pylori"Oxidative-stress resistance mutants of . J. Bacteriol. 184 (12): 3186–93.
- O'Rourke EJ, Chevalier C, Pinto AV, et al. (March 2003). colonization"Helicobacter pylori"Pathogen DNA as target for host-generated oxidative stress: role for repair of bacterial DNA damage in . Proc. Natl. Acad. Sci. U.S.A. 100 (5): 2789–94.
- Michod RE, Bernstein H, Nedelcu AM (May 2008). "Adaptive value of sex in microbial pathogens". Infect. Genet. Evol. 8 (3): 267–85.
- Dorer MS, Fero J, Salama NR (2010). Blanke, Steven R, ed. "Helicobacter pylori"DNA damage triggers genetic exchange in . PLoS Pathog. 6 (7): e1001026.
- Loughlin MF, Barnard FM, Jenkins D, Sharples GJ, Jenks PJ (April 2003). mutants defective in RuvC Holliday junction resolvase display reduced macrophage survival and spontaneous clearance from the murine gastric mucosa"Helicobacter pylori". Infect. Immun. 71 (4): 2022–31.
- Wang G, Maier RJ (January 2008). "Helicobacter pylori"Critical role of RecN in recombinational DNA repair and survival of . Infect. Immun. 76 (1): 153–60.
- Pounder RE, Ng D (1995). "The prevalence of Helicobacter pylori infection in different countries". Aliment. Pharmacol. Ther. 9 (Suppl 2): 33–9.
- Smoak BL, Kelley PW, Taylor DN (March 1994). "Seroprevalence of Helicobacter pylori infections in a cohort of US Army recruits". Am. J. Epidemiol. 139 (5): 513–9.
- Everhart JE, Kruszon-Moran D, Perez-Perez GI, Tralka TS, McQuillan G (April 2000). "Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States". J. Infect. Dis. 181 (4): 1359–63.
- Malaty HM (2007). "Epidemiology of Helicobacter pylori infection". Best Pract Res Clin Gastroenterol 21 (2): 205–14.
- Mégraud F (September 2004). "H pylori antibiotic resistance: prevalence, importance, and advances in testing". Gut 53 (9): 1374–84.
- Mégraud F (1995). "Transmission of Helicobacter pylori: faecal–oral versus oral–oral route". Aliment. Pharmacol. Ther. 9 (Suppl 2): 85–91.
- Cave DR (May 1996). "Transmission and epidemiology of Helicobacter pylori". Am. J. Med. 100 (5A): 12S–17S; discussion 17S–18S.
- Delport W, van der Merwe SW (2007). "The transmission of Helicobacter pylori: the effects of analysis method and study population on inference". Best Pract Res Clin Gastroenterol 21 (2): 215–36.
- Correa P, Piazuelo MB (January 2012). Genome: Implications for Gastric Carcinogenesis"Helicobacter pylori"Evolutionary History of the . Gut Liver 6 (1): 21–8.
- Linz B, Balloux F, Moodley Y et al. (February 2007). "Helicobacter pylori"An African origin for the intimate association between humans and . Nature 445 (7130): 915–8.
- "The Nobel Prize in Physiology or Medicine 2005". Retrieved 2 August 2008.
- Konturek JW (December 2003). and its pathogenetic role in peptic ulcer, gastritis and gastric cancer"Helicobacter pylori"Discovery by Jaworski of (PDF). J. Physiol. Pharmacol. 54 (Suppl 3): 23–41.
- Egan BJ, O'Morain CA (2007). "A historical perspective of Helicobacter gastroduodenitis and its complications". Best Pract Res Clin Gastroenterol 21 (2): 335–46.
- Palmer ED (August 1954). "Investigation of the gastric mucosa spirochetes of the human". Gastroenterology 27 (2): 218–20.
- Steer HW (August 1975). "Ultrastructure of cell migration through the gastric epithelium and its relationship to bacteria" (PDF). J. Clin. Pathol. 28 (8): 639–46.
- Marshall BJ, Warren JR (June 1984). "Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration". Lancet 1 (8390): 1311–5.
- Atwood IV KC (2004). and the making of a myth"H. pylori"Bacteria, Ulcers, and Ostracism? . Retrieved 2 August 2008.
- Borody TJ, Cole P, Noonan S et al. (October 1989). "Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication". Med. J. Aust. 151 (8): 431–5.
- in peptic ulcer disease"Helicobacter pylori". NIH Consensus Statement Online Jan 7–9;12(1):1–23. Retrieved 21 December 2004.
- H. pyloriInformation on tests for from the National Institutes of Health